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Abstract
BioXpress is a gene expression and cancer association database in which the expres-
sion levels are mapped to genes using RNA-seq data obtained from The Cancer
Genome Atlas, International Cancer Genome Consortium, Expression Atlas and publica-
tions. The BioXpress database includes expression data from 64 cancer types, 6361
patients and 17 469 genes with 9513 of the genes displaying differential expression be-
tween tumor and normal samples. In addition to data directly retrieved from RNA-seq
data repositories, manual biocuration of publications supplements the available cancer
association annotations in the database. All cancer types are mapped to Disease
Ontology terms to facilitate a uniform pan-cancer analysis. The BioXpress database is
easily searched using HUGO Gene Nomenclature Committee gene symbol, UniProtKB/
RefSeq accession or, alternatively, can be queried by cancer type with specified signifi-
cance filters. This interface along with availability of pre-computed downloadable files
containing differentially expressed genes in multiple cancers enables straightforward
retrieval and display of a broad set of cancer-related genes.
Database URL: http://hive.biochemistry.gwu.edu/tools/bioxpress
Introduction
Gene expression is considered a key molecular marker for
diagnostic and prognostic assessment of cancer (1–8).
More than a decade ago, gene expression analysis was pro-
posed as a method to complement classification schemes
based on tumor morphology because it was well known
that tumors with similar histopathological appearance can
have considerably different clinical outcomes (6, 9).
These efforts provided the framework by which linking
gene expression with cancer research could be realized (10).
Hanahan and Weinberg (11) in their seminal paper
‘The Hallmarks of Cancer’ discussed the role of over- and
under-expression of key genes in several cancers. The con-
jectures that both diagnosis of somatically acquired lesions
in tumors and genome-wide expression profiling of tumors
would become routine (11) have not yet been realized, but
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we anticipate that this will likely change within the next
decade. With advances in next-generation sequencing
(NGS) technologies, several national and international pro-
jects are underway that aim to capture and analyze the ex-
pression profiles of thousands of tumors (12–14).
Additionally, there are already thousands of publications
that describe over- and under-expression of specific genes
in cancer. Currently, to the best of our knowledge, there is
no integrated view of the expression profiles of the human
genes obtained from NGS technology such as RNA
sequencing (RNA-seq). Moreover, no singular effort is
underway to manually curate data from publications on
cancer-related gene expression, enabling easy comparison
of expression data and knowledge from both small publi-
cations and large-scale studies like The Cancer Genome
Atlas (TCGA: http://cancergenome.nih.gov/) and
International Cancer Genome Consortium (ICGC: https://
icgc.org/). Lack of such efforts prevents us from tracking
our knowledge of expression profiles of genes in different
cancer types as technology improves and more data and in-
formation accumulate. Furthermore, as we move toward
the translation of expression analysis through genomic or
proteomic technologies to the clinic, there is no easy way
to compare a patient’s expression data with that extant
data. BioXpress has been developed as the first step toward
the provision of easy access to gene expression data from
tumor and normal samples, which will be useful for clin-
ical research, diagnostics and prognostics of cancer.
The specific technology used to measure gene expres-
sion significantly affects the cost, comprehensiveness and
the time consumed to perform expression analysis. DNA
microarray and quantitative polymerase chain reaction (q-
PCR) are powerful approaches for measuring gene expres-
sion and have been used for many years. DNA microarray
technology is efficient and cost-effective at the gene expres-
sion level, while q-PCR is considered more sensitive.
However, neither of these approaches can meet the sensi-
tivity and comprehensiveness of the newer RNA-seq tech-
nology (15, 16). Despite the benefits of RNA-seq,
microarrays are often preferentially used due to the higher
cost and lack of standardization of pipelines using the
RNA-seq technology. Once these obstacles are overcome,
it is clear that RNA-seq will become the predominant tool
for expression analysis (17). In addition to expression ana-
lysis, RNA-seq provides a number of other benefits. A sin-
gle RNA-seq experiment output can aid in the discovery of
novel and unannotated transcripts (18), single nucleotide
variation (SNV) identification (19) and more (20). As
RNA-seq technology and the corresponding analytical
approaches grow, the application of this method is becom-
ing indispensable for many scientific disciplines (21–23).
To address this growing presence of RNA-seq data, we
currently focus on large-scale integration of RNA-
seq-based expression data in BioXpress complemented by
manual curation of information from publications report-
ing gene expression associated with cancer. The manual
curation process allows us to collect valuable expression-
related information from peer-reviewed publications from
diverse platforms. Integration of information from both
large-scale studies and publications allows users to easily
compare and contrast expression profiles of their gene(s)
of interest.
The advancement of expression analysis technology has
led to the development of corresponding databases and
standards. For example, the Minimum Information About
a Microarray Dataset initiative (24) provides standards for
microarray data, while databases like the National Center
for Biotechnology Information (NCBI) Gene Expression
Omnibus (GEO) (25) and Array Express (26) have signifi-
cant amounts of microarray data. Secondary databases
that store and provide results and analysis of microarray
and other gene expression data related to cancer such as
CGED (Cancer Gene Expression Database) (27), GENT
(Gene Expression across Normal and Tumor tissue) (28)
and Oncomine (29) are also available. Finally, TCGA and
ICGC data portals and databases, such as Expression Atlas
(30), provide RNA-seq-generated data. All the above-men-
tioned databases provide mechanisms to retrieve gene-spe-
cific information, but, to the best of our knowledge, none
of them allows integrated pan-cancer analysis across mul-
tiple projects. NCBI GEO and European Bioinformatics
Institute (EBI) ArrayExpress, e.g. are public repositories
for high-throughput microarray and NGS functional gen-
omic datasets. A gene symbol-based search can result in
thousands of profiles from GEO Profiles Database. CGED,
on the other hand, provides data specifically obtained
through collaborative efforts of Nara Institute of Science
and Technology, Osaka University Medical School, Kyoto
University Medical School and Osaka Medical Center for
Cancer and Cardiovascular Diseases. GENT provides
Affymetrix microarray data from tumor and normal sam-
ples, while Expression Atlas at EBI provides differential
and baseline expression from several organisms. Similar to
other public repository data, a single search can retrieve
data from many experiments in these resources.
Furthermore, although tools do exist which aim to analyze
the same scope of data, the tools and databases of which
we are aware do not facilitate the expression analysis on
RNA-seq desired here. cBioPortal (31) is a widely popular
resource with an emphasis on mutation analysis.
Currently, Oncomine (29) does provide the means to ana-
lyze expression for microarray data, but not for RNA-seq.
Thus, there is no single tool/resource available
which integrates RNA-seq information that allows
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expression analysis to identify, e.g. cancer relatedness.
Although hundreds of cancer RNA-seq studies are pub-
lished each year, a cancer-centric RNA-seq expression
database that integrates all cancer-related RNA-seq-based
expression data from databases and publications is not
available to the community. Portals like TCGA data portal
and ICGC data portal, which provide RNA-seq-based ex-
pression data, only provide access to raw read counts and
normalized counts: such data cannot be easily used for
comparative analysis across several cancer types and exist-
ing experimental results in publications. In addition, differ-
ent normalization methods are employed by different data
providers, making comparison and cross-type analysis
even more challenging.
The BioXpress database project collects RNA-seq data
from several publicly available sources such as TCGA
(http://cancergenome.nih.gov/), ICGC (12) and Gene
Expression Atlas (30), and uses a standardized method to
identify the expression levels of the genes. Expression levels
of genes are also manually extracted from publications to
supplement information gathered from large-scale studies.
Additionally, all cancer types are mapped to Disease
Ontology (32) terms to facilitate pan-cancer analysis.
Finally, all genes are linked to a comprehensive cancer-
related non-synonymous SNV database, BioMuta (33).
Together, BioMuta and BioXpress provide a detailed view
of the expression and mutations of genes in cancer and
therefore can be used for pan-cancer studies like the one
performed by our group recently (34) and described in this
manuscript.
Data Source and Metrics
The majority of RNA-seq databases provide data either in
FASTQ format (sequence reads) and/or raw read count
data. Read count data are calculated by analyzing the map-
ping file where the reads have already been aligned to a ref-
erence genome. As shown in Figure 1, BioXpress processes
data based on the availability of expression data from
paired data that have both normal and tumor samples
TCGA raw counts TCGA 
data portal
ICGC Expression Atlas
Tumor Normal
HIGH QUALITY
DATA SOURCE
UNIFIED
STATISTICAL
APPROACHES
NORMALIZED
EXPRESSION
RESULT
GENE CENTRIC
EXPRESSION
PROILE
Raw Counts Raw Counts Normalized Counts
DEseq normalization and 
differential expression 
analysis
Deseq normalization Directly passing the 
normalized value to 
BioXpress
Log2 fold change of 
normalized counts
Normalized counts Normalized counts
EXPERIMENT 
DESIGN
P NPPaired samples: both tumor 
and control are available. 
Differenal analysis can be 
performed.
Non-Paired samples: Only 
tumor or normal samples are 
sequenced. 
Differenal expression
Stacked bar chart
Tumor only expression
Box plot
Baseline expression
Heatmap
NPNP
P
NP
Figure 1. Flow chart of the workflow used to create BioXpress. BioXpress processes short reads and read count data through distinct pipelines. Data
are further divided into two groups: paired data that have both normal and tumor samples from the same patient, and non-paired, tumor-only data.
Output in BioXpress is split into three different types: differential expression (stacked bar chart), tumor-only expression (box plot) and baseline ex-
pression data (heatmap). In addition to the data integration approaches shown in the figure, gene expression information is also extracted from
publications.
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from the same patient, and the non-paired data from just
tumor and also from just normal tissue.
The data sources and statistics in terms of number of pa-
tients from each data source are shown in Table 1. To
achieve comprehensiveness, data are collected from TCGA,
the Curated Short Read archive (CSR) (35), ICGC (12),
Gene Expression Atlas (30) and publications (Table 1). It is
important to note that ICGC, at the time of writing this art-
icle, did not contain any data from paired normal and
tumor samples which are not from TCGA. Therefore, the
data in BioXpress are split into three different types: differ-
ential expression, tumor-only expression and baseline ex-
pression data from Illumina Human Body Map project
(http://www.ebi.ac.uk/gxa/experiments/E-MTAB-513).
Data Processing
TCGA data portal
TCGA-Assembler was used to download RNA-seq data
from TCGA data portal. Raw counts data with paired sam-
ples (tumor and normal) were extracted and analyzed using
DEseq R package with default parameters:
method¼ ‘blind’, sharingMode¼ ‘fit-only’, fitType¼ ‘local’
(36). DEseq normalization method has been reported to out-
perform other normalization methods (37). Fold changes,
not absolute expression values, are displayed based on anal-
ysis described above (38). False discovery rates are not
defined due to the low number of replicates for samples.
This approach allows the user to determine the significance
of differentially expressed genes on an individual basis.
ICGC data portal
ICGC contains tumor-only data (normal samples are not
sequenced by the consortium currently). Gene expression
data from tumor samples was downloaded from ICGC
data portal (12) and analyzed using DEseq R package with
default parameters (36).
Expression atlas
Normalized baseline expression was downloaded via
Expression Atlas (http://www.ebi.ac.uk/gxa/download.
html) (30). Because raw read counts are not available for
all data retrieved from Expression Atlas, no additional nor-
malization was performed in BioXpress.
Manual curation from publications
Decades of research on differential expression in tumor and
normal samples has led to thousands of publications.
Although many of these studies are based on samples from
modest numbers of patients, there is value in the systematic
capture and presentation of this information alongside large-
scale studies such as those presented by TCGA and ICGC.
Although it is possible that studies may exhibit discordance,
it is equally possible for the consideration of such additional
experiments to contribute to the ‘big picture’ of differential
expression between tumor and normal samples. We leave it
to the discretion of individual users to decide the significance
of curated publications in application to their studies.
For manual curation of expression data, genes identified
in our previous pan-cancer study were prioritized (34).
In addition to this prioritization, genes annotated by
UniProtKB/Swiss-Prot as associated with cancer and
Cancer Gene Census (http://www.sanger.ac.uk/genetics/
CGP/Census/) (39) were also targeted for manual curation.
This UniProtKB/Swiss-Prot gene list was obtained using
the following search string: organism: ‘Homo sapiens
[9606]’ AND reviewed:yes AND annotation:(type:disease
cancer). Briefly, the manual curation protocol involved
searching PubMed (40) using the gene name (including
synonyms) with accompanying text ‘cancer’ and ‘expres-
sion’. The curator then reviewed the title to shortlist art-
icles which appear to contain gene expression information
related to cancer and have full text available. Abstracts
were then read to identify potential true positive articles.
All such articles were downloaded and read to extract key
information such as cancer type and expression informa-
tion. All cancer types were then mapped to Disease
Ontology terms (32) and added to the BioXpress database.
To date, 536 papers have been filtered to maintain only
those focusing on human cancer after reading the
‘Abstract’ and ‘Introduction’. Among this subset, only
papers including direct evidence reflecting gene expression
Table 1. Statistics of data collected in BioXpress
Source Data type No. of samples/individualsa Tumor/normal
TCGA Raw read count 1320/660b Tumor and normal
ICGC and TCGA Raw read count 6397/6324 Tumor
Expression Atlas baseline Normalized count 1/1 Normal
Literature Published literature Not applicable (135 publications) Tumor and normal comparison
aTypically, each patient contains more than one sequencing sample. Therefore, we provide the number of both samples and individuals.
bThe number of patients is collected from TCGA, ICGC and Expression Atlas baseline projects. Some TCGA patient IDs overlap with the ICGC patient IDs.
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differentiation between normal and cancer tissues were
kept. Filtering then continued with further inspection of
the ‘Materials and Method’ and ‘Results’ sections of each
paper. Some cancer-type abbreviations were taken from
the TCGA Code Table Report (https://tcga-data.nci.nih.
gov/datareports/codeTablesReport.htm), while the rest of
them were named using the following conventions:
first three letters from the first word and the last two let-
ters from the second word. Thus, if the cancer types have a
single word name, all five letters come from this word. In
the event of duplication, letters from the third or fourth
words are used to distinguish between types. Curators
cross-check all manual curation processes. In total, 135
papers concerning 87 genes have been added to the
BioXpress database through biocuration (supplementary
Table S2).
Data Normalization and Analysis
DEseq method is regarded as one of the most robust RNA-
seq normalization methods (37). In the BioXpress pipeline,
raw counts data were normalized by DEseq method fol-
lowed by differentially expressed gene analysis. To com-
pare non-paired samples with normalized results from
DEseq pipeline, the DEseq normalization method was used
[Parameters: library(‘DESeq’), cds¼ newCountDataSet
(data,condition), cds¼ estimateSizeFactors(cds), result¼
counts(cds,normalized¼TRUE)]. For differential expres-
sion analysis, gene expression was normalized based on
each patient, and case and control were considered to-
gether. For tumor expression, all samples were collectively
analyzed across different cancer types and then normal-
ized. Heat map and clustering analysis were performed
using the ‘heatmap’ function from the R package (http://
www.R-project.org/).
Usage and Utility
Scientists can find querying datasets useful to identify ex-
pression levels between disease and normal pairs to dis-
cover differential expression for a gene. They may also
want to research on potential biomarkers or pathways
that lead to tumor formation or want to explore the over-
all expression of specific genes across multiple
cancer types. Users can search BioXpress using HGNC-
approved gene symbols (HUGO Gene Nomenclature
Committee), UniProtKB/Swiss-Prot accessions or RefSeq
accessions. Differentially expressed genes for a specific
cancer type can also be retrieved. Additionally, all data in
BioXpress, including lists of genes significantly differen-
tially expressed in two or more cancer types, can be
downloaded.
Searching using gene name (gene/protein-centric
search)
A search using the HGNC-approved gene symbol or
UniProt/RefSeq accession retrieves differential expression
information (cancer vs. normal), tumor-only expression
data (where normal samples are not available) and baseline
expression information from normal human tissues
(Illumina Human Body Map Project). The example below
provides an overview of a gene/protein-centric search.
Differential expression
The abnormal spindle-like microcephaly-associated
(ASPM) gene is highly expressed in several tumor cell lines
(41) and cancers (42, 43). Searching the BioXpress data-
base using the gene ASPM users can retrieve the differential
expression profile of this gene in different cancers. For
ASPM gene, we can clearly see that this gene appears to be
over-expressed in almost all cancers. Figure 2 provides a
view of the BioXpress interface where the Differential
Expression tab on the top menu bar is selected, and below
it ‘ASPM Expression Profile’ is shown. The default view
provides expression frequency (over- or under-expression)
in the patients. The number of patients for a particular can-
cer type, P value and a variety of additional information is
available in the table below which can be downloaded.
Full cancer names are available on clicking the cancer ab-
breviations in figure and additional details about the data
can be viewed by clicking the ‘Table column description’
link. All columns can be sorted and users can send an e-
mail to the help desk with comments about a specific data
element by clicking on the envelope link available from
each row.
The tab at the top of the stacked bar chart provides an
alternate view where users can see the frequency (number
of patients) of significantly over- or under-expressed genes
(based on a P value cutoff of 0.05). For ASPM, on clicking
the Significant/Freq tab, we can see that this gene is signifi-
cantly over-expressed in more than 25% of the patients in
several cancers. For example, ASPM is over-expressed in
breast invasive carcinoma (DOID:3459; 113 patients),
lung adenocarcinoma (DOID:3907; 50 patients) and
others. Combining the stacked bar frequency expression
(Regulation/Freq) and the Significant/Freq, users can get a
complete overview of the differential expression of a gene
in all cancer types in the database.
Tumor expression
Clicking on the Tumor Expression tab on the top menu bar
shows the expression profile for the ASPM gene from all pa-
tient samples without paired normal data. Although ICGC
does not currently collect any paired data, tumor-only
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expression data can provide an overview of the expression of
a specific gene in different cancer types and can be used in
conjunction with differential and baseline expression data to
better understand the comprehensive expression profile of a
gene. The box plot provides the minimum lower quartile, me-
dian upper quartile and maximum expression value, and
therefore provides a snapshot of the distribution of expression
of a gene in all patients with a specific cancer. For the ASPM
gene, we see that for cervical squamous cell carcinoma
(CESC), the minimum, maximum and the lower and upper
quartile are above the theoretical mean for all cancer types
which could indicate that for CESC this gene has less variabil-
ity in terms of expression in the patients and is expressed at a
higher level compared with other cancers. Therefore, the box
plot allows the user to identify cancer types where the lower
and the upper quartile are short, signifying homogeneity in
the expression of the gene for that specific cancer. The table
below the box plot provides details such as UniProtKB acces-
sion, RefSeq accession and number of samples.
Baseline expression
Clicking the Baseline Expression tab for ASPM gene shows
the heatmap with testis being the only tissue with increased
expression of ASPM. It has been known for some time that
ASPM is over-expressed in testis (41, 44), although the pre-
cise function of this gene in testis development is still un-
known (45).
Searching using cancer type (cancer type
centric search)
Users may want to retrieve a list of genes that are signifi-
cantly differentially expressed in a specific cancer. From
the Home page, clicking on the Search by cancer type tab
allows users to select the cancer type of interest and then
retrieve genes which are either over- or under-expressed.
For example, selecting lung adenocarcinoma and the de-
fault settings (over-expressed; adjusted P value and
P> 0.1) retrieves the 2089 genes, out of which the top ex-
pressed gene is FAM83A (Protein FAM83A; also called
Tumor antigen BJ-TSA-9). It is interesting to note that
FAM83A is considered a promising tumor biomarker of
lung cancer (41). Similarly, the second highly expressed
gene GREM1 (Gremlin) is also known to be over-ex-
pressed in lung cancer (46).
Pan-cancer analysis
The ability to sort, filter and further analyze the gene ex-
pression data collected in BioXpress allows users to com-
pare and contrast expression of genes across many patients
and cancer types. In addition to listing the genes that are
significantly differentially expressed in multiple cancers (as
described in the previous paragraph), Figure 3 provides an
overview of the types of analysis that users can perform
A B C
Figure 3. Clustering and heatmap view of the top 50 differentially expressed genes as reported by BioXpress. Although these graphics were gener-
ated using external tools, the emphasis here is the ability of BioXpress to sort through large amounts of data and return candidate subsets for subse-
quent analysis. (A) Clustering of these genes in different cancer types based on the frequency of patients who have significant differential expression.
Darker colors indicate a higher percentage of patients with such differential expression. (B) For genes which do not have normal samples, the heat-
map shows clustering based on normalized count. Darker colors indicate a higher expression level. (C) Clustering based on baseline expression for
the 50 genes in different tissues. Darker colors indicate higher expression level.
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using the downloaded data. Figure 3A heatmap and clus-
tering were performed based on the percent of patients
who have significantly differentially expressed genes.
Clustering of samples or datasets across multiple cancer
types, known as one type of pan-cancer analysis, is widely
conducted by the community, especially by TCGA
Research Network (47, 48), and is of great interest from
the aspect of personalized and translational medicine. To
select genes that have strong association with transcrip-
tomic changes of tumors, we picked the top 50 genes that
are differentially expressed in the highest percent of sam-
ples. The darker colors in the figure show that several can-
cer types have genes which are differentially expressed in a
majority of the patients (red boxes). The clustering based
on the heatmap indicates that several cancer types have
similar patterns [kidney renal clear cell carcinoma (KIRC)
and kidney renal papillary cell carcinoma (KIRP); head
and neck squamous cell carcinoma (HNSC) and stomach
adenocarcinoma (STAD); lung squamous cell carcinoma
(LUSC) and pancreatic adenocarcinoma (PAAD); thyroid
carcinoma (THCA) and lung adenocarcinoma (LUAD)].
Figure 3B shows analysis results of expression data where
no normal samples are available. The figure provides a
view of cancer types that cluster together based on gene ex-
pression from cancer samples only. On the basis of the
color distribution, it can be seen that several cancers have
similar expression patterns and hence cluster together:
breast cancer (BRCA) and lymphoma (Lymph); ovarian
cancer (OV) and endometrial cancer (Endca); close to
them are endocrine pancreas cancer (PAEN), prostate
adenocarcinoma (PRAD), lung squamous cell carcinoma
(LUSC), leukemia (Leuke) and brain cancer (Braca); KIRC
and THCA; colon adenocarcinoma (COAD), PAAD and
rectum adenocarcinoma (READ) are also clustered. Liver
cancer (Livca) shows a distinct gene expression profile
with all other cancer types listed based on the selected
genes. Figure 3C provides a view of tissues which have
similar expression patterns.
Collection of expression data from multiple cancers as
presented in supplementary Table S1 allow us to identify
genes that are differentially expressed in more than one
cancer type. For example, from this table we can see that
nine genes are differentially expressed in all cancer types
(Table 2). It is important to note that in this particular case
we do not consider the number of patients who have these
genes over- or under-expressed. Therefore, each gene and
its expression in a cancer type needs to be carefully eval-
uated on a case-by-case basis if one is interested in identify-
ing genes which are differentially expressed in majority of
the patients (please see examples in the next paragraph). It
is interesting to note that five of the nine proteins are
glycoproteins, two are phosphoproteins, six of them are
secreted and seven are involved in biological process regu-
lation (based on UniProtKB keyword and Gene Ontology
annotation). This type of filtering and sorting can reveal
ideal candidates for further evaluation as diagnostic or
therapeutic targets. Furthermore, literature evidence re-
veals that eight of the 9 genes in Table 2 are genes known
to be associated with cancer. For example, the first gene
listed in Table 2, CCL21, participates in leukocytes and
cancer cell migration through the CCR7/CCL19 (CCL21)
axis to promote the growth and metastasis of various
tumors such as breast cancer, melanoma, non-small cell
lung cancer, head and neck, gastrointestinal and hemato-
logic cancer (49). Second, c-glutamyltransferase is involved
in cellular glutathione homeostasis, its expression is often
significantly increased in human tumors and its role in
tumor progression, invasion and drug resistance has been
repeatedly suggested (50). Third, alterations in the ubiqui-
tin system have direct or indirect roles in the genesis of
various tumors due to defects in the ubiquitin-dependent
proteolysis of critical house-keeping genes or cell–cycle
elements—p53 is a good example (51). The next genes,
Matrilysin (MMP7), are frequently over-expressed in
human cancer tissues and are associated with cancer pro-
gression (52) and NCAM1 has been demonstrated to be
one of the immunohistochemical markers for lung neuro-
endocrine tumors diagnosis (53), its expression level is up-
regulated in large cell lung tumor cell line H460-M (54).
CHRDL1 is down-regulated (79–89% of 19) in follicular
thyroid carcinoma (55) and the gene, WFDC2 (HE4), con-
tains dispersed evidence: it has been demonstrated to be a
biomarker for ovarian carcinoma (56) and it is known to
be over-expressed in a range of different cell lines including
ovarian, renal, lung, colon and breast lines, and cancers
such as endometrial adenocarcinomas (57, 58) and lung
adenocarcinoma (59). The next gene, LCN2, has a wide
range of functions in different types of cancers (thyroid,
pancreatic, breast and colon cancer), and it is a potential
diagnostic and prognostic marker in both benign and ma-
lignant human diseases (60). Finally, KRT80 and its role in
cancer is not well studied although there is some evidence
that this gene is differentially expressed in certain types of
cancer (61, 62). In addition to this list, a separate, pre-
computed table which lists all genes and their normalized
expression values in tumors across all cancer types is also
provided for download. This table can be used to identify
genes which have, e.g. high variability in expression in cer-
tain cancers or low variability (possible house-keeping
genes).
As mentioned above, one of the key questions in pan-
cancer analysis of gene expression is—are there any genes
which are significantly over- or under-expressed in mul-
tiple cancers in a large number of the patients.
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Table 2. Genes significantly differentially expressed in tumor and normal samples in all cancer types in one or more patients
Gene UniProtKB
AC
Protein name Over-expressed cancer types Under-expressed cancer types
CCL21 O00585 C-C motif che-
mokine 21
KIRC, LIHC, BRCA, THCA, KICH KICH, BRCA, THCA, PAAD, ESCA, KIRC,
COAD, KIRP, STAD, CESC, LIHC, HNSC,
READ, PRAD, BLCA, LUAD, LUSC, UCEC
GGT6 Q6P531 c-glutamyltrans
ferase 6
BRCA,THCA, PAAD, BLCA, STAD,
CESC, LIHC, KIRC, LUAD, UCEC
BLCA, BRCA, STAD, ESCA, KIRC, COAD,
KIRP, HNSC, READ, PRAD, KICH, LUAD,
LUSC
UBD O15205 Ubiquitin D KICH, BRCA, THCA, ESCA, KIRC,
COAD, STAD, CESC, LIHC, HNSC,
READ, PRAD, BLCA, LUAD, LUSC,
UCEC
BRCA, THCA, PAAD, KICH, KIRP, LIHC,
HNSC, PRAD, BLCA
MMP7 P09237 Matrilysin BRCA, STAD, THCA, ESCA, BLCA,
COAD, PAAD, LIHC, HNSC, READ,
PRAD, KIRC, LUAD, LUSC, UCEC
KICH, BRCA, BLCA, KIRP, CESC, LIHC,
HNSC, PRAD, KIRC, LUAD
NCAM1 P13591 Neural cell adhe-
sion molecule
1
BRCA, THCA, KIRC, KIRP, HNSC,
KICH, LUAD, LUSC
KICH, BRCA, STAD, KIRP, THCA, ESCA,
KIRC, COAD, PAAD, CESC, LIHC, HNSC,
READ, PRAD, BLCA, UCEC
CHRDL1 Q9BU40 Chordin-like
protein 1
PRAD, KICH, LIHC, THCA, KIRC PAAD, BRCA, STAD, THCA, ESCA, BLCA,
COAD, KIRP, KIRC, CESC, LIHC, HNSC,
READ, PRAD, KICH, LUAD, LUSC, UCEC
WFDC2 Q14508 WAP four-disul
fide core do-
main protein 2
BRCA, STAD, PAAD, ESCA, KIRC,
CESC, LIHC, HNSC, BLCA, LUAD,
UCEC
KICH, BRCA, THCA, BLCA, COAD, KIRP,
STAD, LIHC, HNSC, READ, PRAD, KIRC,
LUAD, LUSC
LCN2 P80188 Neutrophil gelat
inase-associ-
ated lipocalin
BLCA, BRCA, THCA, PAAD, ESCA,
KIRC, COAD, KIRP, STAD, CESC,
LIHC, READ, PRAD, KICH, LUAD,
LUSC, UCEC
BRCA, THCA, KIRC, KIRP, LIHC, HNSC,
PRAD, BLCA, LUAD, LUSC
KRT80 Q6KB66 Keratin, type II
cytoskeletal 80
BRCA, THCA, PAAD, ESCA, BLCA,
COAD, KIRP, STAD, CESC, LIHC,
READ, PRAD, LUAD, LUSC, UCEC
BLCA, BRCA, THCA, KIRC, LIHC, HNSC,
PRAD, KICH
LIHC¼ liver hepatocellular carcinoma; BLCA¼ bladder urothelial carcinoma; KICH¼ kidney chromophobe; UCEC¼ uterine corpus endometrial carcinoma;
ESCA¼ esophageal carcinoma; CESC¼ cervical squamous cell carcinoma and endocervical adenocarcinoma.
Table 3. Top five genes significantly differentially expressed in tumor and normal samples in >50% of the patients
Gene UniProtKB AC Protein name Over-expressed cancer types Under-expressed cancer types
COL10A1 Q03692 Collagen alpha-1(X) chain BRCA, STAD, BLCA, COAD, HNSC,
LUAD
COL11A1 P12107 Collagen alpha-1(XI) chain BRCA, COAD, HNSC, LUAD, LUSC,
MMP11 P24347 Stromelysin-3 BRCA, BLCA, COAD, HNSC, LUAD
TMPRSS4 Q9NRS4 Transmembrane protease
serine 4
KIRC, LUAD, LUSC, THCA, UCEC
MMP1 P03956 Interstitial collagenase COAD, LUAD, LUSC, HNSC
ADH1B P00325 Alcohol dehydrogenase 1B BLCA, THCA, KIRC, COAD, KIRP,
HNSC, KICH, LUSC, UCEC
MT1H P80294 Metallothionein-1H KICH, KIRC, KIRP, LIHC, THCA
MT1G P13640 Metallothionein-1G KICH, KIRC, KIRP, LIHC, THCA
CHRDL1 Q9BU40 Chordin-like protein 1 BLCA, KICH, KIRC, THCA, UCEC
CA4 P22748 Carbonic anhydrase 4 BRCA, COAD, KIRP, LUAD, LUSC
The genes were sorted based on the number of cancer types they were differentially expressed in.
LIHC¼ liver hepatocellular carcinoma; BLCA¼ bladder urothelial carcinoma; KICH¼ kidney chromophobe; CESC¼ cervical squamous cell carcinoma and
endocervical adenocarcinoma.
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Supplementary Tables S3 and S4 provide the list of genes
that are significantly differentially expressed in greater
than 30% and 50% of the patients. Table 3 lists the top 5
genes (sorted based on the number of cancer types it is dif-
ferentially expressed in) that are significantly over- and
under-expressed in more than 50% of the patients. The
first gene COL11A1 is known to be over-expressed in
various epithelial cancers and is prominently correlated
with invasion and metastasis (63). Its over-expression is
associated with colorectal cancer (64), non-small cell lung
cancer (65) and several other cancers (66). The next gene
MMP11 over-expression is correlated with the aggression
and invasion status of various types of carcinoma and is
almost absent in normal adult organs and can be con-
sidered as a biomarker for diagnosis and prognosis (67,
68). TMPRSS4 is highly expressed in pancreatic, colon,
lung and gastric cancers, and is also expressed in a wide
range of human cancer cell lines and has been demon-
strated to facilitate the invasion, migration and metastasis
of tumor cells (69, 70). MMP1 is highly expressed in gas-
tric carcinoma, breast cancer, lung and other cancers
(71–78). ADH1B is the first gene in the table that is
known to be under-expressed in multiple cancers such as
oral tongue squamous cell carcinoma (79) and intrahe-
patic cholangiocarcinoma (80). MT1H is under-expressed
in adenoid cystic carcinoma of salivary gland, prostate
and liver cancer due to hypermethylation of its promoter
(81, 82). In the next gene MT1G, the promoter is hyper-
methylated which results in its down-regulation in hepato-
blastoma and prostate cancer (83, 84). CHRDL1
interestingly is under-expressed in colorectal cancer (85)
while over-expressed in pancreatic cancer (86) and for
CA4 there is currently no publication associated with ex-
pression of these gene in cancers. We believe that filtering
and sorting of data in BioXpress will help researchers to
focus on expression profiles of genes which currently have
very little published information. Another gene SFRP1
which is also found to be under-expressed in our dataset
in five cancers (>50% of the patients) is known to be
under-expressed in nine cancer types: cancers of the kid-
ney, stomach, small intestine, pancreas, parathyroid, ad-
renal gland, gall bladder, endometrium, renal cell
carcinoma and testis (87).
Downloadable files
Websites are ideal for performing gene and cancer-centric
searches as described above. Some users may wish to per-
form large-scale analysis or filter the data based on add-
itional parameters. To accommodate such users, all data
can be downloaded in tab-delimited format. Additionally,
a table of significantly under- or over-expressed genes in
one or more patients is provided that has the following col-
umns: gene name, UniProtKB accession, protein name,
cancer types where the gene is expressed and count of the
number of cancer types (supplementary Table S1). This
table can be used to quickly identify genes that are differ-
entially expressed in multiple cancer types in one or more
patients. Additional downloads include PubMed
Identifiers (PMIDs) and accessions that were manually
curated (supplementary Table S2) and all data associated
with differential and tumor-only expression. Future plans
include addition of additional tables based on user
requests.
Future Perspective
BioXpress will be updated every 6 months and detailed
statistics for each release will be provided. Such statistics
will allow users to track changes in the database over time.
We will also integrate BioXpress in the High-performance
Integrated Virtual Environment (HIVE) NGS and prote-
omics analysis platform. This integration will allow users
to upload RNA-seq data, map reads to the reference gen-
ome using HIVE Hexagon (88), perform expression ana-
lysis and directly compare results with those available from
BioXpress. As proteomic data become available for differ-
ent cancer types through programs similar to the Clinical
Proteomic Tumor Analysis Consortium (CPTAC) (89), we
will map such data to the genes. We also plan to augment
both data and function based on input from our users.
Some potential new features include the following: add-
ition of cancer subtypes; linking BioXpress to BioMuta
(33) to obtain comprehensive view of expression as it may
relate to mutation; integration of clinical annotations; in-
clusion of additional graphical elements and more. Our
preliminary results show that there is a correlation between
mutation density of a gene and its expression in certain
types of cancer. We intend to explore this further in our fu-
ture studies.
Supplementary Data
Supplementary data are available at Database Online.
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